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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to carry out the additional assessment for taxifolin-rich extract from
Dahurian Larch as a food ingredient in the context of Regulation (EC) No 258/97. The novel food (NF)
is a taxifolin-rich water–ethanol extract from the wood of the Dahurian Larch and contains a minimum
of 90% taxifolin. The Panel considers that the taxifolin-rich extract is sufﬁciently characterised and that
its compositional data and speciﬁcations do not raise safety concerns. The NF is intended to be added
to non-alcoholic beverages, to yogurt and to chocolate confectionery. The Panel considers that the
data on genotoxicity do not raise concern. In a subchronic rat study performed in accordance with
OECD standards, the highest dose tested (i.e. 1,500 mg/kg bw) was considered to be the NOAEL. The
margin of exposure (MOE) of the combined intake (158 mg) from the intended food uses (including
100 mg from food supplements) would result to about 660 for an adult weighing 70 kg. For
adolescents, taking into account a default body weight of 45 kg, the MOE of the combined intake
(146 mg) would be about 460. In the absence of a high percentile intake estimate for children
between 9 and 14 years of age, the Panel considers the P97.5 intake estimate from the intended food
uses (except from food supplements) for children between 10 and 17 years, i.e. 46 mg/day. Taking
into account a default body weight of 29.4 kg (P5 body weight for children aged 10–14 years as
suggested by EFSA Scientiﬁc Committee (2012)), the resulting MOE would be about 960.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to carry out the additional assessment for taxifolin-rich extract from
Dahurian Larch as a food ingredient in the context of Regulation (EC) No 258/97 taking into account
the comments and objections of a scientiﬁc nature raised by the Member States. The assessment
follows the methodology set in Commission Recommendation 97/618/EC of 29 July 1997 concerning
the scientiﬁc aspects and the presentation of information necessary to support applications for the
placing on the market of novel foods (NFs) and NF ingredients and the preparation of initial
assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the Council.
The assessment is based on the data supplied in the original application, the initial assessment by the
competent authority of France, the concerns and objections of the other Member States and the
responses of the applicant.
The NF is a taxifolin-rich water–ethanol extract from the wood of the Dahurian Larch (Larix gmelinii
(Rupr.) Rupr) and contains a minimum of 90% taxifolin ((2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-
2,3-dihydrochromen-4-one, also called (+) trans (2R,3R)-dihydroquercetin). The Panel considers that the
taxifolin-rich extract is sufﬁciently characterised and that its compositional data and speciﬁcations do not
raise safety concerns.
The NF is intended to be added to non-alcoholic beverages (at concentrations up to 0.02 g/L), to
yogurt (up to 0.02 g/kg) and to chocolate confectionery (up to 0.07 g/kg). The target population for
these foods added with taxifolin is the general population from 9 years onwards. In addition, the NF is
also intended for food supplements (100 mg/day) for the general population with an age of 14 years
and above.
The Panel considers that the data on genotoxicity do not raise concern. In a 90-day subchronic rat
study performed in accordance with OECD standards, the highest dose tested (i.e. 1,500 mg/kg body
weight (bw)) was considered to be the no observed adverse effect level (NOAEL).
The margin of exposure (MOE) of the combined intake (158 mg) from the intended food uses
(including 100 mg from food supplements) would result to about 660 for an adult weighing 70 kg. For
adolescents, taking into account a default body weight of 45 kg (P5 body weight for adolescents aged
14–18 years as suggested by EFSA SC (2012)), the MOE of the combined intake (146 mg) would be
about 460. In the absence of a high percentile intake estimate for children between 9 and 14 years of
age, the Panel considers the P97.5 intake estimate from the intended food uses (except from food
supplements) for children between 10 and 17 years, i.e. 46 mg/day. Taking into account a default
body weight of 29.4 kg (P5 body weight for children aged 10–14 years as suggested by EFSA Scientiﬁc
Committee (2012)), the resulting MOE would be about 960. The Panel concludes that the NF, taxifolin-
rich extract from Dahurian Larch, is safe under the proposed conditions of use.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 23 August 2010, the company Ametis JSC submitted a request under Article 4 of the Novel
Food Regulation (EC) No 258/97 to place on the market ‘taxifolin’ as a novel food (NF) ingredient.
On 2 September 2011, the competent authorities of the United Kingdom forwarded to the
Commission their initial assessment report, which came to the conclusion that taxifolin-rich extract may
be placed on the market.
On 20 September 2011, the Commission forwarded the initial assessment report to the other
Member States. Several of the Member States submitted comments or raised objections.
The concerns of a scientiﬁc nature raised by the Member States can be summarised as follows:
• Given that species of the genus Larix are not habitually used as a source of food products, it
would be advisable for the applicant to carry out an analysis of the 3–4% impurities of the NF
on a larger number of more geographically and seasonally diverse lots.
• In the speciﬁcations, the applicant indicates that the extract has a minimum taxifolin content
of 88%. The initial report indicates that the taxifolin content should be set at ‘no less than
90% of the dry weight’: accordingly, and in view of the variations that can be expected from
the initial raw material, the analytical study of ﬁve batches of extract presented by the
applicant would appear to be insufﬁcient.
• No information is provided concerning the possible presence of mycotoxins.
• The applicant should carry out regular testing to ensure that the ﬁnal product is free from
mycotoxin contamination. Although the frequency of this testing could be determined by the
applicant, the applicant should also ensure that this takes into account the range of yeast and
moulds that could be introduced at each stage of production, either via the raw or during storage.
• Documentation certifying the accreditation for one of the testing facilities was not provided.
• Information on the stability of ‘taxifolin’ in different food matrices should be provided.
• The use of ‘taxifolin’ as in ingredient added to the intended food categories raises concern
regarding children.
• It would be useful to have representative data on the occurrence of taxifolin in foodstuffs of
plant origin as well as the resulting estimates for daily intake amounts.
• The intake assessment does not provide ﬁgures for high consumers, but assumes that double
of the average intake of an adult person equates to the 97.5th percentile.
• The description of an in vivo chromosomal aberration test on bone marrow cells of mice had
several limitations: insufﬁcient information about control groups, number of animals used; no
veriﬁcation whether ‘taxifolin’ reached the bones.
• The description of a chromosomal aberration test and a comet assay had similar limitations:
use of a positive control group is not described; it is unclear whether both tests were carried
out on bone marrow, blood, liver and rectal cells; the dose referred to in the body of the text
differs from that in the table.
• The results of the various studies on absorption vary quite considerably. It appears that the
bioavailability of the compounds depends on the source and the compounds of the extract,
thus ‘a speciﬁc study should be performed given that the ingredient in question is intended for
use in a large number of foodstuffs, and contains reactive compounds liable to have synergistic
or antagonistic effects on each other’.
• A mutagenicity study should be carried out in line with the guidelines set out in Commission
Recommendation 97/618/EC of 29 July 1997 in the absence of substantial equivalence.
• Several toxicological studies provided used ‘taxifolin’ from other sources.
• In chronic studies in rats and dogs, only two doses and only male animals were tested. It is
unclear whether all required parameters and organs were studied.
• One developmental study had several limitations (no control, unclear method of administration,
only one dose tested, start of treatment not clearly described).
• Concerns were expressed whether the toxicological studies have been conducted in
accordance with the relevant OECD Guidelines. A 90-day study in rodents in compliance with
the speciﬁcation of the NF and with the 408 OECD Guideline should be conducted.
Toxicological study reports are missing. The toxicological information provided is insufﬁcient for
deriving an acceptable daily intake (ADI).
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• For this type of extract, it is not acceptable to take a supplementary evaluation approach in
which each of the family of compounds most abundant in the extract is examined individually
in order to draw a conclusion on the overall safety of an ingredient.
• The references and/or study reports of the human studies summarised by the applicant in the
application dossier were not provided, nor could they be found in the international specialist
literature. It is therefore not possible to assess the bioavailability, allergenicity and metabolism
of ‘Taxifolin’ in humans.
• The studies were conducted in patients to test potential health beneﬁts, but were not designed
to test the safety and allergenicity in human. It is impossible to draw conclusions on the safety
of ‘taxifolin’ in human.
• With reference to Zuo et al. (2011), ‘Antibacterial and synergy of a ﬂavonol rhamnoside with
antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA).
Phytomedicine, 18 (11) pp: 990–993’, the possible interaction of the product with widely used
antibiotics needs to be investigated. Taxifolin belongs to the same chemical class as
naringenin, which is known to interact with medicinal substances. Possible interaction with
medical substances should be looked into by studying the relevant literature.
• The applicant does not provide conﬁrmation that proteins are absent from the extract, but he
claims that the risk of allergenicity is very low.
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Food Safety
Authority (EFSA) is asked to carry out the additional assessment of ‘taxifolin’ as a food ingredient in
the context of Regulation (EC) No 258/97.
EFSA is asked to carry out the additional assessment and to consider the elements of scientiﬁc
nature in the comments raised by the other Member States.
2. Data and methodologies
2.1. Data
The assessment of the safety of this NF ingredient is based on data supplied in the original
application, the initial assessment by the competent authority of the United Kingdom, the concerns
and objections of the other Member States and the responses of the applicant to these questions and
those of the United Kingdom. In accordance with Commission Recommendation 97/618/EC (EC, 1997),
taxifolin-rich extract derived from Dahurian Larch is allocated to Class 2.2: ‘a complex (non-GM
derived) novel food ingredient the source of the novel food having no history of food use in the
community’. The data are required to comply with the information required for NFs of Class 2.2, i.e.
structured schemes I, II, III, IX, XI, XII and XIII. In its initial assessment report, the competent
authority of the United Kingdom came to the conclusion that the range of uses for the novel ingredient
is acceptable subject to the implementation of quality control measures described in the applicant’s
dossier and related to mycotoxin testing. It is noted that the NF ingredient is intended by the applicant
to be marketed for its antioxidant properties. This assessment concerns only risk that might be
associated with consumption and is not an assessment of the efﬁcacy of ‘taxifolin’ with regard to any
claimed beneﬁt.
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of 29
July 1997 concerning the scientiﬁc aspects and the presentation of information necessary to support
applications for the placing on the market of NFs and NF ingredients and the preparation of initial
assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the Council.
3. Assessment
3.1. Speciﬁcation of the NF
The NF, a taxifolin-rich water–ethanol extract from the wood of the Dahurian Larch (Larix gmelinii
(Rupr.) Rupr), contains a minimum taxifolin ((2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-
dihydrochromen-4-one, also called (+) trans (2R,3R)-dihydroquercetin) of 90% (Table 1). It is intended
to be marketed under the trade name Lavitol®. The NF is a white to pale yellow-coloured powder that
crystallises from hot aqueous solutions.
Safety of taxifolin
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There are two different diastereomers of taxifolin: (2R,3R)-trans and (2R,3S)-cis and the relative
enantiomers (2S,3S) and (2S,3R). This application refers to (+) trans (2R,3R-dihydroquercetin) form of
at least 98% and with no more than 2% of the cis-form. The molecular weight of taxifolin is
304.25 Da (CAS No 480-18-2). The identity of the taxifolin has been conﬁrmed using 1H nuclear
magnetic resonance spectroscopy and chiroptical methods.
Other components in the NF are very minor and include trace amounts of ethanol, metals, inorganic
salts and saponins (Table 2). The usual ranges of components of the NF are provided in Table 3.
Saponins are present at levels of below 0.5%.
Table 1: Speciﬁcation for the novel food ingredient
Speciﬁcation parameter Method of analysis* Limits
Physical
parameters
Moisture GOST* 16,483.7-71 ≤ 10%
Compound
analysis
Taxifolin (m/m) MVI 72-08 (HPLC) ≥ 90.0% of the dry weight
Heavy metals,
Pesticide
Lead ICP/MS ≤ 0.5 mg/kg
Arsenic ICP/MS ≤ 0.02 mg/kg
Cadmium ICP/MS ≤ 0.5 mg/kg
Mercury ICP/MS ≤ 0.1 mg/kg
Dichlorodiphenyltrichloroethane (DDT) Method 2142-80 ≤ 0.05 mg/kg
Residual
solvent
Ethanol USP 32/NF27 <467> < 5,000 mg/kg
Microbial
parameters
(equivalent to
category 3B,
Ph. Eur.)
repeated in
Section XII.1
Total plate count (TPC) USP ≤ 104 CFU/g
Enterobacteria + div.
Gram-negative bacteria
USP ≤ 100/g
Yeast and mould USP ≤ 100 CFU/g
Escherichia coli USP Negative/1 g
Salmonella spp. USP Negative/10 g
Staphylococcus aureus USP Negative/1 g
Pseudomonas spp. USP Negative/1 g
HPLC: high-performance liquid chromatography; ICP/MS: Inductively coupled plasma mass spectrometry; CFU: colony-forming
units.
*: GOST (GOsudarstvenniy Standard, Russian State Standard.
Table 2: Batch analysis results of the Novel Food ingredient based on ﬁve non-consecutive batches
extracted from Dahurian Larch
Speciﬁcation parameter Speciﬁcation Batch 2 Batch 27a Batch 29b Batch 66a Batch 950
Outward appearance White or
straw-coloured
powder
Conform Conform Conform Conform Conform
Moisture ≤ 10% 7.85% 7.85% 4.55% 9.6% 7.85%
Taxifolin (% of the
dry weight)
≥ 90% 92.20% 92.43% 92.36% 92.58 92.20%
Lead (mg/kg) ≤ 0.5 mg/kg 0.001 0.067 0.001 0.043 0.040
Arsenic (mg/kg) ≤ 0.02 mg/kg < 0.001 0.002 < 0.001 0.004 0.003
Cadmium (mg/kg) ≤ 0.5 mg/kg 0.001 0.028 < 0.001 0.028 0.040
Mercury (mg/kg) ≤ 0.1 mg/kg < 0.001 0.010 < 0.001 0.006 0.011
Dichlorodiphenyltrichloroethane
(DDT) (mg/kg)
≤ 0.05 mg/kg < 0.005 < 0.005 < 0.005 < 0.005 < 0.005
Ethanol (mg/kg) < 5,000 mg/kg 197.2 147.1 121.8 177.4 31.5
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According to the certiﬁcate issued by the laboratory performing the test for residual protein, protein
could not be detected in 10 lots of the NF. In response to EFSA’s request to provide information on the
applied method for analysing the presence of residual protein, the applicant informed that the limit of
quantiﬁcation (LOQ) was 0.3 mg/g analysed with the Kjeldahl method in accordance with §64 LFGB
L06.00-7 (German legislation).
The UK Committee referred to the nature of the raw material and asked the applicant whether the
product was tested for the presence of mycotoxins. The applicant indicated that they did not routinely test
for mycotoxins, but the quality control (QC) systems employed in the selection of the raw material,
coupled with routine testing for yeasts and moulds in the resulting sawdust, are adequate. Ten randomly
selected batches of a taxifolin extract, manufactured from January through October of 2011, were tested
in the presence of aﬂatoxins. No aﬂatoxins were found. The Panel accepts that the QC system is adequate.
The Panel considers that the taxifolin-rich extract is sufﬁciently characterised and that its
compositional data and speciﬁcations do not raise safety concerns.
3.2. Effect of the production process applied to the NF
The applicant provided certiﬁcates that the applicant is ISO 9001:2000 certiﬁed for the production
of food and food additives. Stumps of Dahurian Larch wood are sawed, debarked, chopped and
shaved and the ground shavings are dried. The ground wood mass is extracted with 75–80% ethanolic
aqueous solution. The solvent is removed from the extract with vacuum distillation. Taxifolin is
crystallised after addition of water. The ﬁnal product is dried (moisture < 10%) using vacuum
distillation and packaged with taxifolin content of not less than 90%.
The stability of the NF ingredient in the containers for marketing (dark glass bottles) was tested for
3 months under normal conditions (25°C, 65% RH), and for 24 weeks under stressed conditions
(40°C, 75% RH). After storage at 40°C, the amount of taxifolin was 94.5% and 97.5% after 1 week
and after 30 weeks, respectively. In response to the Member States’ comments, the applicant provided
some additional information on the stability of taxifolin in foods. After 1 year of storage of soymilk
concentrate fortiﬁed with taxifolin, there was a decrease in the taxifolin content: at 4°C by 6.8%, at
10°C by 3.2% and at 20°C by 10.3%.
The Panel considers that the production process and the stability are sufﬁciently described and do
not raise safety concerns.
3.3. History of the organism used as the source of the NF
The Panel notes that the source of the NF, Dahurian Larch, Larix gmelinii (Rupr.) Rupr., has no
history of food use.
3.4. Anticipated intake/extent of use of the NF
The applicant originally intended the NF for the use in a wide range of food products including food
supplements and PARNUTS. Following a request from EFSA to revise the anticipated intake, the
applicant decided to modify the intended use categories (Table 4). According to the applicant, the NF
Table 3: Usual range of components of the NF (as per dry substance)
Extract component Content, usual observed range (%)
Taxifolin 90–93
Aromadendrin 2.5–3.5
Eriodictyol 0.1–0.3
Quercetin 0.3–0.5
Naringenin 0.2–0.3
Kaempferol 0.01–0.1
Pinocembrin 0.05–0.12
Unidentiﬁed ﬂavonoids 1–3
Water* 1.5
*: Taxifolin in its hydrated form and during the drying process is a crystal. This results on the inclusion of water of crystallisation
in a quantity of 1.5%.
Safety of taxifolin
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is intended for the general population from the age of 9 years onwards, with the exception of its use
for food supplements which are not intended for children of below 14 years of age.
For the revised intake estimate, the applicant used the spread-sheets1 for chronic consumption
available at the EFSA website on summary statistics of the EFSA Comprehensive Food Composition
database (EFSA, 2011). The intake was calculated for all intended consumer groups (Table 5).
Considering a daily intake of 100 mg taxifolin from supplements and by taking into account the
97.5th percentile intake estimate from the other intended uses (Table 4), the combined intake from all
intended food uses would result to 158 mg for an adult and 146.2 mg adolescents.
The Panel notes that the intake estimate was performed with use levels of the NF which slightly
deviate from the intended use levels (intended use level for beverages: 0.02 g/L vs use level used for
the intake assessment: 0.025 g/L and 0.02 g/kg for yogurt vs 0.019 g/kg for fermented milk
products). The applicant noted that despite that all ‘ﬂavoured fermented milk and dairy products
fermented milk’ as a whole food category was used for the intake estimate the NF is only intended to
be used for yogurts from this category. The Panel also notes the conservative approach and
assumptions applied in the applicant’s intake estimate (i.e. use of ‘consumers only’, food categories
Table 4: Updated intended uses and use levels for the NF as food ingredient
Food category Proposed food use
Proposed max use levels within these
foods as food ingredient (g/L or g/kg)
Beverages(a) Non-alcoholic beverages 0.02 g/L
Milk products(a) Yogurt, ca. 7.5% fat (0.025% by fat mass) 0.02 g/kg
Sugar, preserves,
confectionery(a)
Chocolate confectionery, ca. 35% fat
(0.02% by fat mass)
0.07 g/kg
Dietary
supplements(b)
100 mg/day
(a): Intended for the general population from the age of 9 years onwards.
(b): Intended for the general population from the age of 14 years onwards.
Table 5: Estimated intake levels of taxifolin for the intended food categories and target groups*
(children are included upon EFSAs request although they are not among the target
groups)
Food category
Use level
(g/kg)
Mean
(mg/day)
95th percentile
(mg/day)
97.5th percentile
(mg/day)
Adolescents
(from 10 years
up to 17 years
of age)
Non-alcoholic
beverages
0.0250 10.5 20.4 30.3
Flavoured fermented
milk and dairy
products
0.019 2.4 5.8 7.5
Chocolate products 0.070 2.5 7.6 8.4
Combined
consumption levels for
all three categories
15.4 33.8 46.2
Adults
(≥ 18 years of
age)
Non-alcoholic
beverages
0.0250 9.4 28.8 36.4
Flavoured fermented
milk and dairy
products
0.019 4.1 11.2 13.9
Chocolate products 0.070 2.3 6.0 7.7
Combined
consumption levels for
all three categories
15.8 46.0 58.0
*: The applicant based its estimates on ‘consumers only’.
1 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
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used, summing up the high percentiles of each category for deriving the high percentiles for the intake
from all categories.)
3.5. Information from previous exposure to the NF
In response to the Member States’ questions, the applicant provided some information on the
occurrence of taxifolin enantiomers in foods of plant origin. Taxifolin is present in apple ﬂesh
(1,300 mg/kg) and apple skin (7,400 mg/kg) (Vega-Villa et al., 2009). The most abundant taxifolin
enantiomers in apple skin corresponded to the (2R,3S)-()glycoside (41% of the total taxifolin) and
the (2S,3R)-(+)aglycone (17% of the total taxifolin) (Vega-Villa et al., 2009). Also, other foods have
been reported to contain taxifolin such as red onions (98 mg/kg; Slimestad et al., 2007), tomato, olive
oil, sorghum grain, white grapes, strawberries, mulberries (21 lg/g FW; Zhang et al., 2008), acai,
peanuts, pine seeds (172 mg/100 g; Lantto et al., 2009), thyme, citrus fruits, white wine and beer
(1 mg/L; Gerh€auser, 2005). With regard to the concerned (+)2R,3R-diastereoisomer, information about
its occurrence in foods has been provided only for tomatoes (27% of total taxifolin) and apple
(< 0.03% of total taxifolin) (Vega-Villa et al., 2009, 2011) with most of the taxifolin stereoisomers
present as glycosides.
The applicant provided a list of 57 food supplements containing taxifolin from the Dahurian Larch.
The applicant claimed that by April 2009, over 250 products containing taxifolin were registered with
the regulatory bodies of the Russian Federation. Among these products, 142 were food supplements,
over 40 were other food products and over 70 were cosmetic products, recommended adult dosages
range from 5 to 100 mg of taxifolin per day. The applicant provided sales ﬁgures and stated that
18 tonnes of taxifolin (from larch wood) were sold by the applicant to be used within dietary
supplements mainly in Russia, Switzerland, USA and Canada.
3.6. Nutritional information on the NF
Considering the composition and the anticipated daily intakes of the novel food ingredient, the
Panel considers it unlikely that the consumption of the NF would be nutritionally disadvantageous.
3.7. Microbiological information on the NF
The ﬁnal product is routinely tested to conﬁrm the absence of a number of pathogenic
microorganisms in accordance with the European Pharmacopeia. Analysis of ﬁve batches demonstrated
compliance with the speciﬁcation (Table 1). The Panel considers that microbiological information does
not raise safety concerns.
3.8. Toxicological information on the NF
The application describes a number of safety studies and, in response to questions raised by the
Member States, the applicant conﬁrmed that the subchronic and reproductive toxicity studies were
carried out with their taxifolin product. Other studies had used taxifolin preparations from other
manufacturers, using the same or very similar methods of extraction. The applicant also provided the
speciﬁcation of the taxifolin extract used by Shkarenkov et al. (1998), who carried out a number of the
toxicological studies cited in the application. This extract contained comparable amounts of taxifolin
and other identiﬁed ﬂavonoids to the applicant’s product.
3.8.1. Genotoxicity
After submission of the original application a number of genotoxicity studies complying with the
rules of Russian Good Laboratory Practice (GLP) (issued by the Ministry of Health of the Russian
Federation) have been submitted with the NF. None of these studies were conducted following OECD
Guidelines.
In an Ames test with only three strains of Salmonella Typhimurium (TA100, TA98 and TA97) using
the plate incorporation method, taxifolin induced an increase in the number of revertant colonies at
the highest dose tested (1,000 lg/plate) in the presence of a metabolic activation system (S9 mix) and
a dose-related increase at the two highest doses (500 and 1,000 lg/plate) in the absence of S9 mix in
strains TA97 and TA98 (Durnev, 2011a).
No effect of taxifolin was seen in an in vivo comet assay in the bone marrow, liver and blood of
mice (Durnev, 2011b), an in vivo chromosomal aberration test using mice (Durnev, 2011c), and a
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genotoxicity study in Drosophila melanogaster (Durnev, 2011d). The Panel considered that these
studies contained considerable weaknesses and requested new studies to be performed in accordance
with the respective OECD test guideline. In response, the applicant provided a bacterial reverse
mutation test (OECD TG 471) (Ametis, 2013a) and an in vitro micronucleus test in human lymphocytes
(OECD TG 487) (Ametis, 2013b).
The NF was tested for its potential to induce gene mutations in the bacteria reverse mutation assay
(Ametis, 2013a). The test substance Lavitol (93.7% purity) was tested (using the plate incorporation
method) in the Salmonella Typhimurium strains TA1535, TA1537, TA98, TA100 and the Escherichia coli
strain WP2uvrA (pKM101) at dose levels up to 5,000 lg/plate, both with and without the addition of
S9-mix. The test item was dissolved in dimethyl sulfoxide (DMSO). Appropriate positive and negative
controls were included. The study was performed according to GLP and OECD test guideline 471.
Toxicity was observed in all strains at the highest dose level evident as a reduction in the growth of
the bacterial background lawn. In two independent experiments, dose-related increases in the number
of revertant colonies were obtained for strains TA98 and TA1537 and to a lesser extent for TA100 in
both the presence and absence of S9-mix. The Panel concludes that the NF showed clear evidence of
mutagenic activity under the test conditions used.
The NF was tested for its ability to induce micronuclei in cultured human peripheral blood
lymphocytes (Ametis, 2013b). Human lymphocyte cultures were exposed to Lavitol (93.7% purity) for
3 h in the presence and absence of S9-mix, and for 20 h in the absence of S9-mix. The vehicle was
DMSO. The study was performed according to GLP and OECD test guideline 487. The concentrations
used in the main micronucleus test were selected based on preliminary cytotoxicity tests by calculating
the cytokinesis-block proliferative index (CBPI). In the main test, the highest concentrations selected
for micronucleus analysis were 650 lg/mL for the 3-h treatment in the presence and absence of S9-mix
(57.8% and 58.0% cytotoxicity, respectively), and 200 lg/mL for the 20-h treatment in the absence of
S9-mix (53.5% cytotoxicity). No increases in the frequency of micronucleated cells were seen. The
Panel concludes that the NF was neither clastogenic nor aneugenic under the test conditions used.
At request from EFSA for an additional in vivo genotoxicity study, the applicant also provided a
comet assay to assess the potential of taxifolin to induce DNA strand breaks in the colon, duodenum
and liver of Crl:CD (SD) rats (Ametis, 2015). Animals were treated orally with taxifolin at dose levels of
500, 1,000 and 2,000 mg/kg per day on three occasions with the second dose being administered
approximately 24 h after the ﬁrst dose, and with the third dose being administered approximately 21 h
after the second dose, 3 h before sampling. As no mortalities or clinical signs of reaction were
observed between the sexes in a preliminary toxicity test, the comet test was performed using male
animals only. All animals were dosed orally using a dose volume of 10 mL/kg. The vehicle control
group received puriﬁed water and the positive control group received ethyl methanesulfonate (EMS) at
200 mg/kg. No statistically signiﬁcant increases in the median % tail intensity (TI) were observed in
either the colon, duodenum or liver of male Crl:CD(SD) rats administered Lavitol at any dose level,
compared to vehicle control values. The positive control compound, EMS, produced statistically
signiﬁcant increases of 48% in the group mean median % TI when compared to vehicle control
values. Some small incidences of bodyweight loss were observed across all groups in the comet test
on Day 3. The Panel concludes that taxifolin did not cause an increase in DNA strand breaks or
cytotoxicity in the colon, duodenum or liver of male Crl:CD (SD) rats.
Overall, the Panel notes that the NF was positive for mutagenic activity in the bacterial reverse
mutation test. An in vitro micronucleus test showed a negative outcome. The genotoxic potential was
further investigated in an adequately performed in vivo genotoxicity test in three tissues (comet assay)
with a negative outcome. The Panel notes that the approach followed the ‘EFSA Scientiﬁc opinion on
genotoxicity testing strategies applicable to food and feed safety assessment’ (EFSA SC, 2011). The
Panel concludes that the NF is not considered to be of genotoxic concern.
3.8.2. Absorption, distribution, metabolism, excretion
The Panel notes that none of the absorption, distribution, metabolism, excretion (ADME) studies
were testing the NF as speciﬁed in this application.
In general, large differences in the bioavailability of taxifolin in rats have been reported. In one
study, trace amounts of taxifolin were detected in rat plasma after oral administration (10–100 mg/kg
body weight (bw)). Plasma taxifolin was measured in samples obtained 3, 6, 10, 15, 20, 25, 30, 40,
50, 60, 90, 120, 150, 180, 240 and 300 min after dosing. When compared with intravenous
administration, a bioavailability ﬁgure of 0.17% was calculated (Wang et al., 2009).
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In another rat study with taxifolin produced by the applicant, male rats were given 12.5, 25 or
50 mg taxifolin/kg bw by single oral administration or 50 mg/kg bw by intravenous administration
(Seredin et al., 2007). In this study, taxifolin given orally was rapidly absorbed from the
gastrointestinal (GI) tract, and reached a maximum concentration in the blood plasma after 30 min
with undetectable levels after 8 h. Taxifolin was detectable at highest concentrations not only in the
blood plasma and kidneys but also in the liver heart, spleen, brain, skeletal muscles, lungs for up to
24 h after administration (Seredin et al., 2007). In this study, the bioavailability of taxifolin compared
to intravenous administration was 24%.
High-performance liquid chromatography (HPLC) analysis of rat urine by Seredin et al. (2007) found a
number of peaks which corresponded to derivatives of taxifolin. The authors report that around 8% of
the original dose given orally (50 mg/kg bw) was seen in urine during the ﬁrst 24 h after administration,
but none was seen in the following 24 h. No taxifolin was detected in the faeces after 24 and 48 h. In a
separate study (Voskoboinikova et al., 1993), the urinary excretion of taxifolin over a 24-h period did not
exceed 6% of the intravenous dose administered, with a near linear increase with dose.
A study (Brown and Grifﬁths, 1983) reported the conversion of taxifolin to 3’- or 4’-O-
methyltaxifolin in rats.
Another study in two human volunteers consuming 2 g of taxifolin reported its conversion into a
number of hydroxyphenylacetic acids. It was reported that the same metabolites were excreted as in
similar experiments with quercetin (Booth and De Eds, 1957).
The bioavailability of taxifolin in rabbits was 36% after ingestion of 8–80 mg/kg bw (Pozharitskaya
et al., 2009).
Taxifolin was rapidly absorbed in rats from the GI tract. Absorbed taxifolin was distributed to the
blood plasma, liver, heart, spleen, brain, skeletal muscles, lungs and kidneys. Metabolites of taxifolin
are excreted through the urine. Excretion of unaltered taxifolin through urine is low.
3.8.3. Acute and subacute toxicity
The toxicity of a taxifolin-rich extract from larch was assessed following single intragastric
administration to rats and mice in doses up to 12,000 mg/kg bw (Shkarenkov et al., 1998).
Intragastric administration of a single dose of 12,000 mg/kg bw resulted in no animal deaths.
As a response to the Member States’ comments, the applicant has provided a subacute study in
rats. The compound tested in this study is a commercial product, which is in conformity with the
speciﬁcations of the NF.
In the subacute study, groups of 20 Wistar rats (10/sex) were given 10,000 or 15,000 mg NF/kg
bw by gavage for 7 days (Celyico, 2008). All animals survived but soft stools and porphyrin around the
eyes were seen in some test animals (no individual data). Erythrocyte counts in female rats were
statistically signiﬁcantly lower in the two dose groups compared to the control group, 6.8 and 6.7 vs
9.6 (1012/L). No effect on erythrocytes was seen in male rats. No differences between groups were
seen for the urinalysis and the organ weights. ‘Oedema’ in a non-speciﬁed part of the gastrointestinal
tract was observed in 11 rats from both dose groups and one rat from the control group. Oedema of
the liver was seen in four rats from both dose groups. Slight foci of fresh haemorrhage and
heterogeneous nuclei of cardiomyocytes were seen in rats from test and control groups. No
information about severity was provided. The Panel notes the high doses tested.
3.8.4. Subchronic toxicity
In the original dossier, the applicant provided a 90-day study which did not meet OECD standards
and was therefore considered by the Panel not suitable to draw conclusions on the subchronic toxicity
in rats.
As a response to an EFSA request for a 90-day study in accordance with OECD standards, the
applicant has provided a new subchronic study in rats. The compound tested taxifolin with a purity of
90.5%.
In the study, groups of 20 rats (Wistar albino rats) (10/sex) were given 0, 50, 150 or 1,500 mg
Lavitol/kg bw for 90 days (Tselyico, 2016 – unpublished study report). In addition, a high-dose
recovery group and a control recovery group of 5 rats/sex were observed during a 28-day treatment-
free period. The rats were about 8 weeks old at the start of the study. The Lavitol was dissolved in a
1% starch solution and administered orally via a stomach tube. The study complies with OECD test
guideline no 408 (1998) and followed the rules of GLP (issued by the Ministry of Health of the Russian
Federation). The animals were housed 5/sex per cage and fed a natural-ingredient diet.
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No mortality was seen during the study. Occurrence of aggression was seen in two females and
three males from the high-dose group and in one female and two males of the mid-dose groups. In
the control groups, aggressive behaviour was only seen in one female. For the female rats, this can be
related to the signiﬁcant increase in the occurrence of abrasions, which was seen in the high-dose
females and judged to be caused by ﬁghting between the animals. The presence of ﬁve animals per
cage could be a contributing factor behind these observations. No difference in body weight was seen
between the male and female groups. In males, the absolute weight gain was signiﬁcantly lower in the
high-dose group compared to controls from day 1–90, and in the recovery groups from day 1–118.
Food consumption was not signiﬁcantly different between groups but tended to be lower in the high-
dose male group compared with the control group. The lower body weight gain seen in high-dose
males could be consequence of the lower feed intake and also the observed lower initial body weights
of this group.
No difference in the ophthalmological examination, the results of electrocardiogram and behavioural
activity were seen between the groups. No statistically signiﬁcant differences were seen between the
control and the Lavitol-dosed groups in haematology parameters, except for a signiﬁcant increase in
platelet counts for the low-dosed males. In the female recovery groups, a signiﬁcant higher leucocyte
count was seen in the high-dose group, and in males, a signiﬁcant increase in RBC was seen for the
high-dose group. In clinical biochemistry, alkaline phosphatase was signiﬁcantly higher in the low-dose
males and level of triglycerides was signiﬁcantly lower in the female mid-dose group. In the recovery
period, triglyceride level was signiﬁcantly lower in the high-dosed females. No differences were seen
between the male groups. Urinalyses and relative organ weights showed no statistically signiﬁcant
differences between groups. Absolute organ weights were only displayed on an individual level. The
gross pathological examination showed deformation of the fundus of the stomach in one high-dosed
male and female, and in one male from the high-dose recovery group. No stomach-related ﬁndings
were seen in the other groups. The stomach-related ﬁndings were supported by microscopic
observations found to be pronounced hyperaemia of the capillaries of the mucosa, moderate oedema
and inﬁltration of the submucosa, thickening of the serous membranes and inﬂammatory inﬁltration of
the surface layer of the mucous membrane and could result from an irritating effect on the stomach
mucosa due to the application of test material directly into the stomach. Hypertrophy of the adrenal
glands was seen in two male and two female rats from the high-dose group and in one male and
female from the high-dose recovery group. The adrenal hypertrophy was also seen in one female
control and one low-dose male and female. The adrenal ﬁndings were supported by the microscopic
examination, which were described as an increase in the mass of cortical and medullar substances,
small haemorrhage around small arteries and capillaries. The macroscopic ﬁndings in the adrenals and
stomach could be explained by aggressive behaviour leading to stress and local irritation, respectively.
Furthermore, the incidences are small, also found in the control group and are not supported by other
ﬁndings. The Panel therefore considers that the no observed adverse effect level (NOAEL) of the study
is 1,500 mg/kg bw per day, the highest dose tested.
3.8.5. Developmental toxicity
As a response to the Member States’ comments, the applicant has provided a developmental
toxicity study in rats. The compound tested is a commercial product, which is in conformity with the
speciﬁcations of the NF.
In the developmental toxicity study, groups of 20 pregnant female rats (Rattus norvegicus) were
given 0, 75 or 1,500 mg NF/kg bw during gestation day from 6 to 16. An additional group was given
75 mg NF/kg bw during gestation day from 1 to 19 (Celyico, 2011). The rats were about 3 months old
at the start of the study. The test compound was dissolved in a 1% starch solution and administered
orally via a stomach tube. Endpoints included, for dams, clinical signs, mortality, body weight,
functional observations, clinical chemistry, fetal survival, and gross, skeletal and visceral examination of
fetuses, for the offspring, body weight, sensory motor evaluation, clinical chemistry and necropsy and
histopathological examination were carried out. The study complies with the rules of GLP (issued by
the Ministry of Health of the Russian Federation). The study design is very similar to the one proposed
in OECD TG 414. All dams survived and no signs of toxicity were observed during the prenatal dosing.
The administration of the NF caused no effects to the fetuses regarding litter size, weight, formation of
organs and general development. No embryotoxic or teratogenic effect of the NF was seen in the
study at dose level up to 1,500 mg/kg bw.
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3.8.6. Human studies
The applicant provided a summary on 15 human studies with in total 18 study arms in which
taxifolin (from larch) was administered to patients with a relatively wide range medical conditions,
including atherosclerosis, arterial hypertension, ischaemic heart disease, vascular encephalopathy,
diabetes, Lyme disease, patients awaiting operations on ovaries and chronic pulmonary obstructive
diseases. According to the tabulated summary provided by the applicant, taxifolin was administered in
addition to a standard therapy for the underlying disease. The applicant states that in total 507
patients were given taxifolin (40–120 mg/day) for 2 weeks to 3 months and no side effects were
reported.
The Panel considers that no conclusions on the safety can be made from the information provided.
3.8.7. Allergenicity
Cases on occupational allergenicity to larch wood dust have been reported (Kespohl et al., 2012).
According to the applicant, allergenicity to the NF has not been reported from Russia, Switzerland,
USA and Canada where the NF is marketed.
According to the information provided in Section 1 (Speciﬁcations), protein was not detected at a
LOQ of 0.3 mg/g. Considering the production process, which includes crystallisation and estimated
intake of the NF, the amount of protein intake from the NF would be very low, i.e. less than 47 lg
(considering the high percentile intake estimate for adults, i.e. 158 mg).
Based on this information, the Panel considers that the likelihood of allergenicity is low.
4. Discussion
The NF is a taxifolin-rich water–ethanol extract from the wood of the Dahurian Larch (Larix gmelinii
(Rupr.) Rupr) and contains a minimum of 90% taxifolin ((2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,
3-dihydrochromen-4-one, also called (+) trans (2R,3R)-dihydroquercetin). The Panel considers that the
taxifolin-rich extract is sufﬁciently characterised and that its compositional data and speciﬁcations do not
raise safety concerns.
The NF is intended to be added to non-alcoholic beverages (at concentrations up to 0.02 g/L), to
yogurt (up to 0.02 g/kg) and to chocolate confectionery (up to 0.07 g/kg). The target population for
these foods added with taxifolin is the general population from 9 years onwards. In addition, the NF is
also intended for food supplements (100 mg/day) for the general population with an age of 14 years
and above.
The Panel considers that the data on genotoxicity do not raise concern. In a 90-day subchronic rat
study performed in accordance with OECD standards, the highest dose tested (i.e. 1,500 mg/kg bw)
was considered to be the NOAEL.
The margin of exposure (MOE) of the combined intake (158 mg) from the intended food uses
(including 100 mg from food supplements) would result to about 660 for an adult weighing 70 kg. For
adolescents, taking into account a default body weight of 45 kg (P5 body weight for adolescents aged
14–18 years as suggested by EFSA SC (2012)), the MOE of the combined intake (146 mg) would be
about 460. In the absence of a high percentile intake estimate for children between 9 and 14 years of
age, the Panel considers the P97.5 intake estimate from the intended food uses (except from food
supplements) for children between 10 and 17 years, i.e. 46 mg/day. Taking into account a default
body weight of 29.4 kg (P5 body weight for children aged 10–14 years as suggested by EFSA Scientiﬁc
Committee (2012)), the resulting MOE would be about 960.
5. Conclusions
The Panel concludes that the NF food, taxifolin-rich extract from Dahurian Larch, is safe under the
proposed conditions of use.
Documentation provided to EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for an opinion on the safety of ‘taxifolin’. SANCO E6/AK/bs Ares (2012)1443458
dated 5 December 2012.
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2) Dossier on ‘Taxifolin’ submitted by Ametis. Received on 5 December 2012. Additional
information was submitted on 11 and 13 December 2013, 2 March, 12 August and 28
September 2015, 19 July and 24 October 2016.
3) Initial assessment report carried out by the United Kingdom: ‘Advisory Committee for Novel
Foods and Processes. Opinion on a taxifolin-rich extract from Dahurian Larch’. Assessment of
safety for the consumer, in accordance with European Regulation 258/97 concerning novel
foods and novel food ingredients (August 2011).
4) Member States’ comments and objections.
5) Response by the applicant to the initial assessment report and the Member States’ comments
and objections.
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Abbreviations
ADI acceptable daily intake
ADME absorption, distribution, metabolism, excretion
bw bodyweight
CAS Chemical Abstracts Service
CBPI cytokinesis-block proliferative index
CFU colony-forming units
DDT dichlorodiphenyltrichloroethane
DMSO dimethyl sulfoxide
EMS ethyl methanesulfonate
FW Fresh weight
GI gastrointestinal
GLP Good Laboratory Practice
GOST GOsudarstvenniy Standard (Russian State Standard)
HPLC high-performance liquid chromatography
ICP/MS inductively coupled plasma mass spectrometry
ISO International Organization for Standardization
LOQ limit of quantiﬁcation
MOE margin of exposure
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NF novel food
NOAEL No observed adverse effect level
OECD Organisation for Economic Co-operation and Development
QC quality control
TI tail intensity
RBC Red blood count
TPC total plate count
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